COR · NYSE · Health Care Distributors
Health Care Distributors company based in Conshohocken, Pennsylvania.
Last close, Oct 1, 2026
$309.78
Adjusted for splits and dividends
Last 12 months
-0.6%
S&P 500 +14.3% over the same dates
Market value
$59.1B
Last close × shares outstanding
Bets against the stock: 4.31M shares sold short (2.3% of shares outstanding), -4.8% vs the previous count, 3.4 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
3 sales
$4.4M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$321B
+9.3% vs the year before
Net income, fiscal 2025
$1.55B
As reported in the annual filing
Shares outstanding
191M
As of Jul 31, 2026
In fiscal 2025 the company spent $435M buying back its own shares and $437M on dividends. Cash actually paid, from its cash-flow statement.
Stock since the trade -2.7% · S&P 500 +1.3% · to Oct 1Traded 42 days after results
18K → 17K shares held−7% of their stake
A board member of Cencora sold $411K of Cencora shares. Nobody planned it ahead of time.
Director plans to sell ~$411K of Cencora
Planned, from payOfficer plans to sell ~$430K of Cencora
Planned, from payOfficer plans to sell ~$3.35M of Cencora
Planned, from payOfficer sold ~$321K of Cencora
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
0 approvals or clearances and 8 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last 12 months, adjusted daily closes
Adjusted close went from $311.77 on Oct 1, 2025 to $309.78 on Oct 1, 2026 (-0.6%). Disclosed trades in the last 12 months: 3 insider purchases, 13 insider sales (4 under pre-arranged plans), 4 Congress purchases, 2 Congress sales. 1 group of purchases by several insiders within a few days.
Short sale volume: 42.7% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 47.4%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Top officer leaving
“Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026.”
1 insider sold ~$3.64M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
